Education
About Us
Working with TipRanks
Follow Us
Meiragtx Holdings Plc (MGTX)
NASDAQ:MGTX
MGTX Stock Chart & Stats
$7.38
-$0.03(-0.47%)
At close: 4:00 PM EST
$7.38
-$0.03(-0.47%)
Day’s Range― - ―
52-Week Range$4.55 - $9.73
Previous CloseN/A
Volume124.17K
Average Volume (3M)468.00K
Market Cap
$582.75M
Enterprise Value$739.42M
Total Cash (Recent Filing)$14.84M
Total Debt (Recent Filing)$88.06M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Mar 12, 2026EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding80,490,890
10 Day Avg. Volume392,383
30 Day Avg. Volume468,003
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)6.27
Price to Sales (P/S)12.78
P/FCF Ratio-3.89
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue26.97
Enterprise Value/Gross Profit65.76
Enterprise Value/Ebitda-5.15
Forecast
1Y Price Target
$21.50Price Target Upside191.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Meiragtx Holdings News
MGTX FAQ
What was Meiragtx Holdings Plc’s price range in the past 12 months?
Meiragtx Holdings Plc lowest stock price was $4.55 and its highest was $9.73 in the past 12 months.
What is Meiragtx Holdings Plc’s market cap?
Meiragtx Holdings Plc’s market cap is $582.75M.
When is Meiragtx Holdings Plc’s upcoming earnings report date?
Meiragtx Holdings Plc’s upcoming earnings report date is Mar 12, 2026 which is in 56 days.
How were Meiragtx Holdings Plc’s earnings last quarter?
Meiragtx Holdings Plc released its earnings results on Nov 13, 2025. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.49 by -$0.13.
Is Meiragtx Holdings Plc overvalued?
According to Wall Street analysts Meiragtx Holdings Plc’s price is currently Undervalued.
Does Meiragtx Holdings Plc pay dividends?
Meiragtx Holdings Plc does not currently pay dividends.
What is Meiragtx Holdings Plc’s EPS estimate?
Meiragtx Holdings Plc’s EPS estimate is -0.57.
How many shares outstanding does Meiragtx Holdings Plc have?
Meiragtx Holdings Plc has 80,490,890 shares outstanding.
What happened to Meiragtx Holdings Plc’s price movement after its last earnings report?
Meiragtx Holdings Plc reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.49. Following the earnings report the stock price went down -4.619%.
Which hedge fund is a major shareholder of Meiragtx Holdings Plc?
Currently, no hedge funds are holding shares in MGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Meiragtx Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.50 (191.33% Upside)
$21.50 (191.33% Upside)
Blogger Sentiment
Bullish
MGTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 97.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.0%
Last 30 Days ▲ 14.7%
Last 30 Days ▲ 14.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.87%
12-Months-Change
Fundamentals
Return on Equity
-611.42%
Trailing 12-Months
Asset Growth
-36.73%
Trailing 12-Months
Company Description
Meiragtx Holdings Plc
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
MGTX Stock 12 Month Forecast
Average Price Target
$21.50
▲(191.33% Upside)
Technical Analysis
Ownership Overview
19.68% Insiders
1.98% Mutual Funds
64.91% Other Institutional Investors
9.96% Public Companies and
Individual Investors